SGMT
Sagimet Biosciences Inc

1,896
Mkt Cap
$242.29M
Volume
280,700.00
52W High
$11.41
52W Low
$1.73
PE Ratio
-4.04
SGMT Fundamentals
Price
$7.33
Prev Close
$7.45
Open
$7.45
50D MA
$7.29
Beta
0.00
Avg. Volume
486,733.95
EPS (Annual)
-$1.45
P/B
1.84
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy
Sagimet Biosciences Inc. (SGMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·8d ago
News Placeholder
More News
News Placeholder
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical...
PR Newswire·9d ago
News Placeholder
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·1mo ago
News Placeholder
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·2mo ago
News Placeholder
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
Zacks·4mo ago
News Placeholder
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
Zacks·5mo ago
News Placeholder
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate
Many investors eagerly await further announcements at the conference, with some buying based on rumors of a significant update.
Stocktwits·10mo ago
News Placeholder
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily...
PR Newswire·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA Research Report) and Sagimet Biosciences, Inc. Class A...
TipRanks Financial Blog·1y ago

Latest SGMT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.